Pronova's 4th-qtr EBITA boosted by Omacor
Lysaker, Norway-based Pronova BioPharma says strong demand for Omacor (concentrated omega-3 polyunsaturated fatty acids), up 61% year-on-year, helped fourth-quarter 2007 earnings before interest, taxes and amortization reach 122.4 million Norwegian kroner ($22.3 million) versus 106.6 million kroner.
During the period, revenues rose 32.3% to 269.4 million driven by strong US growth. Profit before tax totaled 37.8 million kroner vs 50.4 million kroner, impacted by non-recurring items and the increase in net financial expenses, while net profit reached 25.7 million kroner vs 37.4 million kroner.
Hopeful GSK's takeover of Lovaza will promote sales growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze